人肝细胞癌中去唾液酸糖蛋白受体 1 的表达。
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
机构信息
Department of In Vivo Pharmacology - Oncology, Merck Research Laboratories, Merck & Co., Inc., West Point, PA (BS).
出版信息
J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.
Abstract
Human hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Currently, surgical resection is the only effective treatment for HCC if the tumor is resectable. Small molecule, biologics and siRNA anti-cancer drugs have been explored for the treatment of HCC. Selective targeting to tumor tissue rather than normal liver in HCC patients is still a challenge. Galactosamine-mediated targeting delivery of anti-cancer drugs in the liver has been tested because its receptor, asialoglycoprotein receptor 1 (ASGPR1), is expressed in the liver and not in other human tissues. We examined ASGPR1 expression levels by immunohistochemistry in HCC with different grades. Guidance for a targeting delivery strategy for anti-cancer drugs to HCC is suggested in this report.
摘要
人肝癌（HCC）是全球第五大常见癌症。目前，如果肿瘤可切除，手术切除是 HCC 的唯一有效治疗方法。小分子、生物制剂和 siRNA 抗癌药物已被探索用于 HCC 的治疗。在 HCC 患者中，使抗癌药物选择性靶向肿瘤组织而不是正常肝脏仍然是一个挑战。已经测试了半乳糖胺介导的抗癌药物在肝脏中的靶向递送来治疗 HCC，因为其受体，即去唾液酸糖蛋白受体 1（ASGPR1），在肝脏中表达，而不在其他人体组织中表达。我们通过免疫组织化学检查了不同分级 HCC 中的 ASGPR1 表达水平。本报告提出了一种用于 HCC 靶向递药策略的指导意见。
相似文献
1
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.
J Histochem Cytochem. 2013 Dec;61(12):901-9. doi: 10.1369/0022155413503662. Epub 2013 Aug 26.
2
Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Biomacromolecules. 2018 Jun 11;19(6):2330-2339. doi: 10.1021/acs.biomac.8b00358. Epub 2018 May 29.
3
Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
World J Gastroenterol. 2015 Mar 14;21(10):2918-25. doi: 10.3748/wjg.v21.i10.2918.
4
Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Drug Deliv. 2017 Nov;24(1):20-29. doi: 10.1080/10717544.2016.1225856.
5
Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin.
PLoS One. 2014 Apr 24;9(4):e96185. doi: 10.1371/journal.pone.0096185. eCollection 2014.
6
Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma.
Colloids Surf B Biointerfaces. 2019 Oct 1;182:110397. doi: 10.1016/j.colsurfb.2019.110397. Epub 2019 Jul 24.
7
A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Liver Transpl. 2018 Jul;24(7):946-960. doi: 10.1002/lt.25062.
8
Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
J Hepatol. 2017 Aug;67(2):282-292. doi: 10.1016/j.jhep.2017.02.024. Epub 2017 Mar 6.
9
New Small-Molecule Glycoconjugates of Docetaxel and GalNAc for Targeted Delivery to Hepatocellular Carcinoma.
Mol Pharm. 2021 Jan 4;18(1):461-468. doi: 10.1021/acs.molpharmaceut.0c00980. Epub 2020 Dec 2.
10
Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk.
Oncotarget. 2015 Dec 15;6(40):42952-62. doi: 10.18632/oncotarget.5518.
引用本文的文献
1
Sorafenib-Drug Delivery Strategies in Primary Liver Cancer.
J Funct Biomater. 2025 Apr 21;16(4):148. doi: 10.3390/jfb16040148.
2
Unlocking the Potential of Phyto Nanotherapeutics in Hepatocellular Carcinoma Treatment: A Review.
J Hepatocell Carcinoma. 2024 Nov 16;11:2241-2256. doi: 10.2147/JHC.S483619. eCollection 2024.
3
Identification and Analysis of Phenolic Compounds in L. and Its Lipid-Lowering Activity In Vitro.
Foods. 2024 Oct 28;13(21):3438. doi: 10.3390/foods13213438.
4
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.
Adv Pharm Bull. 2024 Oct;14(3):513-523. doi: 10.34172/apb.2024.061. Epub 2024 Jul 31.
5
Detection of γ-OHPdG in Circulating Tumor Cells of Patients With Hepatocellular Carcinoma as a Potential Prognostic Biomarker of Recurrence.
Gastro Hep Adv. 2024 Apr 24;3(6):809-820. doi: 10.1016/j.gastha.2024.04.006. eCollection 2024.
6
Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer.
Biomolecules. 2024 Aug 19;14(8):1031. doi: 10.3390/biom14081031.
7
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.
MAbs. 2024 Jan-Dec;16(1):2383013. doi: 10.1080/19420862.2024.2383013. Epub 2024 Jul 25.
8
The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.
J Med Virol. 2024 Apr;96(4):e29579. doi: 10.1002/jmv.29579.
9
Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent.
Nat Nanotechnol. 2024 Jun;19(6):846-855. doi: 10.1038/s41565-023-01585-y. Epub 2024 Feb 16.
10
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes.
Signal Transduct Target Ther. 2024 Feb 14;9(1):42. doi: 10.1038/s41392-024-01754-y.
本文引用的文献
1
Bioinformatics analysis reveals potential candidate drugs for HCC.
Pathol Oncol Res. 2013 Apr;19(2):251-8. doi: 10.1007/s12253-012-9576-y. Epub 2013 Jan 23.
2
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
3
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.
4
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
J Liposome Res. 2012 Sep;22(3):224-36. doi: 10.3109/08982104.2012.662653. Epub 2012 Mar 5.
5
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Hepatology. 2012 Aug;56(2):622-31. doi: 10.1002/hep.25679. Epub 2012 Jun 11.
6
Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.
PLoS One. 2011;6(9):e24582. doi: 10.1371/journal.pone.0024582. Epub 2011 Sep 16.
7
FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria.
Cancer Lett. 2011 Jul 28;306(2):214-22. doi: 10.1016/j.canlet.2011.03.009. Epub 2011 Apr 11.
8
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.
9
RNA interference as therapeutics for hepatocellular carcinoma.
Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):106-15. doi: 10.2174/157489211793980097.
10
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma.
Mol Syst Biol. 2010 Aug 24;6:402. doi: 10.1038/msb.2010.58.
Zotero 插件